DNA · Ginkgo Bioworks Holdings Inc
United States · RS rating 61 · As of 2026-11-03
| Price | 10.76 USD |
|---|---|
| 1-day change | +9.2% |
| RS rating (overall / 1M / 3M / 12M) | 61 / 14 / 86 / 38 |
| Stage | Advancing |
| Composite / Minervini / CANSLIM score | 41 / 54 / 56 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +46.0% |
| Sales growth Q/Q | -14.0% |
| Distance from 52-week high | +28.2% |
| Market cap (USD) | $476.8M |